Allarity Therapeutics Secures $20M in Highly Dilutive Debt Financing with Onerous Terms

summarizeSummary

Allarity Therapeutics entered into a Note Purchase Agreement to receive $20 million in cash through two secured promissory notes totaling $20.93 million in principal, with significant interest and restrictive covenants.

check_boxKey Events

• Secured $20 Million in Cash

  The company received $10 million for a Promissory Note A-1 and $10 million into a controlled deposit account for a Secured Promissory Note B.

• Issued $20.93 Million in Principal Debt

  The A-1 Note has an original principal of $10.93 million (including a $900k OID and $30k expenses) at 9% interest, and the B Note has a $10 million principal at 5% interest, both maturing in 18 months.

• Onerous Debt Terms

  The notes include trigger events that can increase the outstanding balance by 5-10% per event, leading to acceleration at a 15% default interest rate.

• Restrictive Covenants

  The agreement includes covenants that limit future debt or equity issuances, particularly those with variable price mechanics, which are common for micro-cap companies.

auto_awesomeAnalysis

This financing provides a substantial cash infusion for Allarity Therapeutics, critical for its operations given its micro-cap status. However, the terms are highly unfavorable, including an original issue discount, high interest rates, and trigger events that can significantly increase the outstanding debt and lead to acceleration. The total principal amount of the debt ($20.93 million) exceeds the company's current market capitalization, indicating a distressed financing scenario. The restrictive covenants also limit future financing flexibility, making this a costly and potentially burdensome capital raise despite providing immediate liquidity.